Does Vyvanse Cause Anxiety?
Vyvanse (lisdexamfetamine), a stimulant used for ADHD and binge-eating disorder, lists anxiety as a common side effect. Clinical trials and post-marketing data show it affects 8-13% of patients, often appearing early in treatment.[1][2] The drug increases dopamine and norepinephrine, which can heighten alertness but also trigger anxiety symptoms like restlessness, nervousness, or panic in sensitive individuals.
Who Gets Anxiety from Vyvanse?
Risk is higher in adults (up to 14%) than children (around 5-8%), and more common during dose increases or with higher strengths like 70mg.[1] Pre-existing anxiety disorders amplify this; FDA labeling warns stimulants may worsen them.[2] Teens and those with heart conditions face elevated risks due to overlapping sympathetic nervous system effects.
How Does Vyvanse Trigger Anxiety?
As a prodrug converting to dextroamphetamine, Vyvanse boosts catecholamines, mimicking fight-or-flight responses. This can cause jitteriness or exacerbate underlying issues. Paradoxically, untreated ADHD often includes anxiety, so Vyvanse may reduce it long-term for some by improving focus—studies show net anxiety drops after 4-6 weeks in responders.[3]
What Do Patients Report About Anxiety on Vyvanse?
User forums and adverse event databases like FAERS log thousands of anxiety cases, with some describing "intense panic" starting day one, while others note it fades.[4] A 2022 review found 10-15% discontinue due to psychiatric effects, including anxiety.[5]
How to Manage Anxiety While Taking Vyvanse?
Start at low doses (20-30mg) and titrate slowly. Doctors often pair it with SSRIs or recommend lifestyle tweaks like caffeine avoidance. Switching to non-stimulants like atomoxetine reduces anxiety risk by 50% in comparative trials.[6] Monitor with scales like the GAD-7; if anxiety persists beyond two weeks, reassess diagnosis.
When Should You Worry About Vyvanse-Induced Anxiety?
Seek immediate care for severe symptoms like chest pain, rapid heartbeat, or suicidal thoughts—rare but listed as serious risks.[2] Long-term, chronic anxiety may signal tolerance or misuse. No evidence links it to permanent anxiety disorders when used as prescribed.
[1]: Vyvanse Prescribing Information, Takeda Pharmaceuticals (FDA-approved label, 2023).
[2]: FDA Adverse Event Reporting System (FAERS) data on lisdexamfetamine.
[3]: Adler et al., J Clin Psychiatry (2009); long-term ADHD trial.
[4]: Drugs.com user reviews and EudraVigilance reports.
[5]: Cortese et al., Lancet Psychiatry (2022); stimulant side effect meta-analysis.
[6]: Newcorn et al., J Am Acad Child Adolesc Psychiatry (2015); atomoxetine vs. lisdexamfetamine comparison.